PaxMedica, Inc.

Equities

PXMD

US70424C2035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.7398 ^USD	+5.06%		-2.77%	-2.27%

Apr. 16	PaxMedica, Inc. Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness	CI
Apr. 12	Sector Update: Health Care Stocks Slipping Late Afternoon	MT

PaxMedica, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 09, 2023 at 05:01 pm EDT

PaxMedica, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 3.49 million compared to net income of USD 0.019032 million a year ago. Basic loss per share from continuing operations was USD 4.08. Diluted loss per share from continuing operations was USD 4.08.
For the six months, net loss was USD 7.32 million compared to net income of USD 1.88 million a year ago. Basic loss per share from continuing operations was USD 9.18 compared to basic earnings per share from continuing operations of USD 3.23 a year ago. Diluted loss per share from continuing operations was USD 9.18 compared to USD 0.85 a year ago.

Latest news about PaxMedica, Inc.

PaxMedica, Inc. Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness	Apr. 16	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	Apr. 12	MT
Top Midday Gainers	Apr. 12	MT
Major US Banks' Lower Earnings Drag Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday	Apr. 12	MT
PaxMedica, Inc. Achieves Key Milestone in the Development of Pax-101 and Provides Update on Potential NDA Submission	Apr. 11	CI
PaxMedica, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Certain Warrants of PaxMedica, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2024.	Feb. 18	CI
Certain Common Stock of PaxMedica, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2024.	Feb. 18	CI
HC Wainwright Starts PaxMedica With Buy Rating, $3 Price Target	Dec. 04	MT
PaxMedica Raises $7 Million From Public Offering	Nov. 22	MT
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	Nov. 20	MT
Top Midday Decliners	Nov. 20	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	Nov. 20	MT
PaxMedica Prices $7 Million Public Offering of Shares, Warrants; Stock Slumps	Nov. 20	MT
PaxMedica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Nov. 07	MT
Top Midday Gainers	Nov. 07	MT
PaxMedica, Inc. acquired Certain Suramin Research Assets from Rediscovery Life Sciences AKI LLC for $0.1 million.	23-10-30	CI
PaxMedica Undertakes 1-for-17 Reverse Stock Split	23-10-30	MT
Wall Street Set to Open Lower as GDP, Jobless Claims Higher Than Expected	23-10-26	MT
Paxmedica, Inc. Holds Important Fda Type-B Meeting to Review Pax-101 Pivotal Trial Data	23-10-26	CI
Sector Update: Health Care Stocks Decreasing Late Afternoon	23-08-16	MT
Sector Update: Health Care Stocks Lower Wednesday Afternoon	23-08-16	MT
PaxMedica Adds Chairman Role to CEO; Shares Fall	23-08-16	MT
PaxMedica, Inc. Announces Executive Changes	23-08-16	CI

Chart PaxMedica, Inc.

Duration

Period

More charts

Company Profile

PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its lead program PAX-101 is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders fragile X syndrome (FXS), FXTAS, ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7398 USD

Average target price

3 USD

Spread / Average Target

+305.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PAXMEDICA, INC.	-2.27%	5.52M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research